Erin O. Wissler Gerdes

TL;DR: “Hit-and-run” treatment with senolytics, which in the case of D’+ Q have elimination half-lives <11 h, significantly decreases senescent cell burden in humans.

TL;DR: The discovery of senolytic drugs, agents that selectively eliminate senescent cells, created a new route for alleviating age‐related dysfunction and diseases and, as anticipated for agents targeting fundamental aging mechanisms that are ‘root cause’ contributors to multiple disorders, potential applications ofsenolytics are protean.

TL;DR: Roles of senescent cells in neurodegenerative diseases and potential implications of senolytic agents as an innovative treatment are considered and agents that selectively target these cells are targeted in preclinical models are considered.

TL;DR: Early preclinical data using senolytics, agents that target senescent cells, show promising results in several aging and disease models as mentioned in this paper, indicating reduced senescent cell burden in adipose tissue of diabetic kidney disease patients and improved physical function in patients with idiopathic pulmonary fibrosis.